Eli Lilly (LLY) shares fell 1.77% to $1017.72 on February 18, 2026, underperforming the broader market as investors reassess the company's valuation following a period of significant growth.
- Analysts are weighing a high 45.0x P/E ratio against a discounted cash flow analysis that suggests the stock remains undervalued relative to its $1040.00 previous close.
- The company is preparing for the potential Q2 2026 U.S. launch of orforglipron, a next-generation oral obesity drug, to maintain its competitive edge in the weight-loss market.
- The stock's decline reflects sector rotation and valuation caution, contrasting with gains in the S&P 500 (+0.74%) and NASDAQ (+1.22%).